Literature DB >> 17980710

Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants--Hakomori's concepts revisited.

Reiji Kannagi1, Jun Yin, Keiko Miyazaki, Mineko Izawa.   

Abstract

Incomplete synthesis and neo-synthesis are two major concepts for cancer-associated alterations of cell surface carbohydrate determinants, formulated by Hakomori and collaborators almost 25 years ago. These concepts are still as relevant and useful as ever for cancer-associated alteration of carbohydrate determinants. Incomplete synthesis of carbohydrate determinants occurs through the epigenetic silencing of glycogenes through DNA methylation and/or histone modification in the early stage cancers. The natural selection of more malignant cancer cells occurs through acquisition of hypoxia resistance by constitutively activated hypoxia inducible factors (HIFs) in the advanced stages of cancers. HIFs induce transcription of several important glycogenes, and lead to neo-synthesis of carbohydrate determinants. For instance, expression of sialyl Lewis A/X is induced by epigenetic silencing of glycogenes in the early stages, and is further accelerated in the advanced stages by hypoxia-induced transcription of several glycogenes. Expression of GM2 ganglioside is induced in cancers by altered glycosyltransferase activities, and its N-glycolyl sialic acid content increases by hypoxia-induced transcription of a sialic acid transporter gene. N-glycolyl GM2 thus reflects two cancer-associated genetic abnormalities in a single determinant, and has high cancer specificity. Every carbohydrate determinant is synthesized through multiple steps, each of which is affected by cancer-associated genetic abnormality. Superiority of carbohydrate determinants as cancer-specific molecules over protein determinants is demonstrated in that a single carbohydrate determinant can reflect multiple cancer-associated genetic abnormalities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17980710     DOI: 10.1016/j.bbagen.2007.10.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  33 in total

Review 1.  Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example.

Authors:  Haitham A Badr; Dina M M AlSadek; Motawa E El-Houseini; Christopher T Saeui; Mohit P Mathew; Kevin J Yarema; Hafiz Ahmed
Journal:  Biomaterials       Date:  2016-11-25       Impact factor: 12.479

Review 2.  Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Authors:  L G Durrant; P Noble; I Spendlove
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

3.  L1CAM from human melanoma carries a novel type of N-glycan with Galβ1-4Galβ1- motif. Involvement of N-linked glycans in migratory and invasive behaviour of melanoma cells.

Authors:  Dorota Hoja-Łukowicz; Paweł Link-Lenczowski; Andrea Carpentieri; Angela Amoresano; Ewa Pocheć; Konstantin A Artemenko; Jonas Bergquist; Anna Lityńska
Journal:  Glycoconj J       Date:  2012-04-29       Impact factor: 2.916

Review 4.  Glycosylation and its implications in breast cancer.

Authors:  Danielle A Scott; Richard R Drake
Journal:  Expert Rev Proteomics       Date:  2019-07-25       Impact factor: 3.940

5.  The effect of epigenetic regulation of fucosylation on TRAIL-induced apoptosis.

Authors:  Kenta Moriwaki; Megumi Narisada; Taku Imai; Shinichiro Shinzaki; Eiji Miyoshi
Journal:  Glycoconj J       Date:  2010-10-16       Impact factor: 2.916

Review 6.  Glycosylation in cancer: mechanisms and clinical implications.

Authors:  Salomé S Pinho; Celso A Reis
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

7.  Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012.

Authors:  Nancy Leymarie; Paula J Griffin; Karen Jonscher; Daniel Kolarich; Ron Orlando; Mark McComb; Joseph Zaia; Jennifer Aguilan; William R Alley; Friederich Altmann; Lauren E Ball; Lipika Basumallick; Carthene R Bazemore-Walker; Henning Behnken; Michael A Blank; Kristy J Brown; Svenja-Catharina Bunz; Christopher W Cairo; John F Cipollo; Rambod Daneshfar; Heather Desaire; Richard R Drake; Eden P Go; Radoslav Goldman; Clemens Gruber; Adnan Halim; Yetrib Hathout; Paul J Hensbergen; David M Horn; Deanna Hurum; Wolfgang Jabs; Göran Larson; Mellisa Ly; Benjamin F Mann; Kristina Marx; Yehia Mechref; Bernd Meyer; Uwe Möginger; Christian Neusüβ; Jonas Nilsson; Milos V Novotny; Julius O Nyalwidhe; Nicolle H Packer; Petr Pompach; Bela Reiz; Anja Resemann; Jeffrey S Rohrer; Alexandra Ruthenbeck; Miloslav Sanda; Jan Mirco Schulz; Ulrike Schweiger-Hufnagel; Carina Sihlbom; Ehwang Song; Gregory O Staples; Detlev Suckau; Haixu Tang; Morten Thaysen-Andersen; Rosa I Viner; Yanming An; Leena Valmu; Yoshinao Wada; Megan Watson; Markus Windwarder; Randy Whittal; Manfred Wuhrer; Yiying Zhu; Chunxia Zou
Journal:  Mol Cell Proteomics       Date:  2013-06-13       Impact factor: 5.911

Review 8.  Altered sphingolipid metabolism induced by tumor hypoxia - new vistas in glycolipid tumor markers.

Authors:  Jun Yin; Keiko Miyazaki; Rebecca L Shaner; Alfred H Merrill; Reiji Kannagi
Journal:  FEBS Lett       Date:  2009-11-11       Impact factor: 4.124

Review 9.  Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.

Authors:  Austin W T Chiang; Hratch M Baghdassarian; Benjamin P Kellman; Bokan Bao; James T Sorrentino; Chenguang Liang; Chih-Chung Kuo; Helen O Masson; Nathan E Lewis
Journal:  J Biomed Sci       Date:  2021-06-22       Impact factor: 8.410

10.  Transcriptional regulation of fucosyltransferase 1 gene expression in colon cancer cells.

Authors:  Fumiko Taniuchi; Koji Higai; Tomomi Tanaka; Yutaro Azuma; Kojiro Matsumoto
Journal:  ScientificWorldJournal       Date:  2013-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.